Flash Finance

Poly Medicure LimitedPOLYMEDCorporate

Healthcare Medical Instruments & Supplies Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,593.80
MCap ₹16,155 Cr · P/E 48.0
Poly Medicure Limited — Stock analysis & AI research Poly Medicure Limited — Seasonality — best & worst months Poly Medicure Limited — Technical indicators & charts Poly Medicure Limited — Technical setup — score, trend, support & resistance Poly Medicure Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Small Cap Stocks List 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹431 Cr
Sales · Jun 2026
+12.3% YoY
₹121 Cr
Operating Profit · Jun 2026
+18.9% YoY
28.0%
OPM % · Jun 2026
+5.7% YoY
₹88 Cr
Net Profit · Jun 2026
+0.2% YoY
₹8.69
EPS · Jun 2026
+0.1% YoY

📝 Poly Medicure Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Poly Medicure Limited reported revenue of ₹431 crore for the quarter ended June 2026 (Q1 FY27), up 12.3% from ₹384 crore in the same quarter last year, and down 2.7% sequentially over the March 2026 quarter.

Net profit rose 0.2% year-on-year to ₹88 crore, from ₹88 crore. Earnings per share (EPS) came in at ₹8.69.

Operating profit stood at ₹121 crore — an operating margin (OPM) of 28.0%, compared with 26.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Poly Medicure Limited posted revenue of ₹1,692 crore, a growth of 5.7% over FY25, with a net profit of ₹336 crore (up 1.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,740 crore with a net profit of ₹337 crore.

Valuation snapshot

At the current price of ₹1,593.80, POLYMED has a market capitalisation of ₹16,155 crore and a trailing P/E of about 48.0.

Within the Medical Instruments & Supplies industry, it is the 2nd-largest of the 3 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 62.42%, foreign institutional investors (FIIs) 5.57%, domestic institutional investors (DIIs) 16.08%, public shareholders 15.94% of Poly Medicure Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹16,155 Cr
Current Price ?
₹1,593.8
P/E ?
48.01below ind
Industry P/E ?
100.10
P/B ?
5.29
P/S ?
9.29
P/FCF ?
-329.69
Enterprise Value ?
₹16,407 Cr
EV/EBITDA ?
35.23
PEG ?
1.85
Earnings Yield ?
2.2%
Dividend Yield ?
0.22%
Profitability & Returns
Sales (TTM) ?
₹1,740 Cr
OPM ?
26.8%
Profit after tax (TTM) ?
₹337 Cr
EPS (TTM) ?
₹33.20
ROCE ?
15.0%
ROE ?
11.0%
ROA ?
9.5%
Growth
Sales — latest qtr ?
₹431 Cr
PAT — latest qtr ?
₹88 Cr
YoY qtr sales growth ?
12.3%
YoY qtr profit growth ?
0.2%
Sales growth (3y) ?
16%
Sales growth (5y) ?
17%
Profit growth (3y) ?
26%
Profit growth (5y) ?
22%
Financial Health
Debt ?
₹252 Cr
Debt to Equity ?
0.08
Interest Coverage ?
25.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
62.42%
Change in promoter holding ?
-0.02%
Pledged percentage ?
N/A
Market
Return 3 months ?
-5.2%
Return 6 months ?
8.6%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 272293306320321361367402411421384417448443431 +12.3% -2.7%
Operating Profit 688285838497101113116116102111113121121 +18.9% -0.1%
Other Income 14913131716172722244134231529 -30.3% +91.0%
Interest 522233333233444 +55.8% +9.6%
Depreciation 141515151616192021212324252626 +15.9% +1.8%
Profit Before Tax 64738178829496117113116117118106107119 +1.3% +10.9%
Net Profit 485761596171728785878889788188 +0.2% +8.8%
EPS 4.955.996.316.176.417.357.538.618.488.558.688.797.737.958.69 +0.1% +9.3%
OPM % 25.1% 28.0% 27.9% 25.8% 26.3% 27.0% 27.5% 28.1% 28.1% 27.6% 26.5% 26.6% 25.2% 27.3% 28.0% +5.7% +2.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,601 Cr ₹1,692 Cr ₹1,740 Cr +5.7%
Operating Profit ₹446 Cr ₹446 Cr ₹466 Cr +0.2%
OPM % 27.83% 26.38% 26.77% -5.2%
NPM % 20.68% 19.87% 19.34% -3.9%
Other Income ₹90 Cr ₹113 Cr ₹101 Cr +26.0%
Depreciation ₹81 Cr ₹98 Cr ₹101 Cr +21.0%
Interest ₹11 Cr ₹14 Cr ₹15 Cr +24.1%
EBIT ₹365 Cr ₹349 Cr ₹364 Cr -4.4%
PBT ₹442 Cr ₹448 Cr ₹450 Cr +1.3%
Tax ₹28 Cr ₹29 Cr ₹31 Cr +3.2%
Net Profit ₹331 Cr ₹336 Cr ₹337 Cr +1.6%
EPS ₹33.17 ₹33.15 ₹33.16 -0.1%
Material Cost ₹139 Cr ₹130 Cr ₹155 Cr -6.6%
Employee Cost ₹73 Cr ₹70 Cr ₹89 Cr -3.9%
Extraordinary Items — ₹-7 Cr ₹-7 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 48485151 +0.0%
Reserves 1,1861,4102,6943,002 +11.4%
Borrowings 137164172252 +46.5%
Other Liabilities 167199224246 +9.8%
Total Liabilities 1,5381,8213,1403,550 +13.1%
Fixed Assets 5988311,0471,223 +16.8%
CWIP 78719390 -3.2%
Investments 1812211,1271,243 +10.3%
Other Assets 681699873994 +13.9%
Total Assets 1,5381,8213,1403,550 +13.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 197256237245 +3.4%
Cash from Investing Activity -189-237-1,191-268 +77.5%
Cash from Financing Activity -8-1795328 -97.1%
Net Cash Flow -02-25 +350.0%
Free Cash Flow -40-13-87-49 +43.7%
CFO/OP 96%94%73%77% +5.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Days Payable 95896658 -12.1%
Debtor Days 76727897 +24.4%
Inventory Days 222194215194 -9.8%
Cash Conversion Cycle 203177226232 +2.7%
Working Capital Days 655273259 +254.8%
ROCE % 19%22%18%15% -16.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 62.44%62.42%62.42%62.42%62.42% +0.0%
FIIs 11.41%9.77%9.41%5.92%5.57% -5.9%
DIIs 11.72%13.53%13.84%15.60%16.08% +3.1%
Public 14.43%14.28%14.34%16.08%15.94% -0.9%
No. of Shareholders 71,14264,40067,75073,41473,643 +0.3%

⚖️ Peer comparison

Industry: Medical Instruments & Supplies · 3 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 LENSKART LENSKART SOLUTIONS ₹681.90 118,107 180.2 9,634 668 20.8% 6.9% — — 43.3% 274.5%
2 POLYMED Poly Medicure ₹1,720.90 17,443 55.4 2,024 313 22.8% 15.5% 13.9% -5.1% 30.3% -8.4%
3 AGARWALEYE DR AGARWALS ₹475.30 15,068 101.3 2,207 185 28.2% 8.4% 21.6% 52.4% 26.1% 44.8%
❓ Frequently asked questions
What was Poly Medicure Limited's revenue in Q1 FY27?
Poly Medicure Limited reported revenue of ₹431 crore for the quarter ended June 2026 (Q1 FY27), up 12.3% from ₹384 crore in the same quarter last year, and down 2.7% sequentially over the March 2026 quarter.
What was Poly Medicure Limited's net profit in Q1 FY27?
Net profit rose 0.2% year-on-year to ₹88 crore, from ₹88 crore. Earnings per share (EPS) came in at ₹8.69.
What is POLYMED's market capitalisation and P/E ratio?
At the current price of ₹1,593.80, POLYMED has a market capitalisation of ₹16,155 crore and a trailing P/E of about 48.0.
Who owns Poly Medicure Limited? (shareholding pattern)
As of Jun 2026, promoters held 62.42%, foreign institutional investors (FIIs) 5.57%, domestic institutional investors (DIIs) 16.08%, public shareholders 15.94% of Poly Medicure Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI